NCT00400634 - Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG

CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

CERE-120 5.4 x 10\^11 vg

PROCEDURE

Sham Surgery

Bilateral partial thickness burr holes placed, no intraparenchymal injections

Trial Locations (9)

Mount Sinai School of Medicine, New York

Pennsylvania Hospital, Philadelphia

Duke University Medical Center, Durham

University of Alabama, Birmingham, Birmingham

Cleveland Clinic, Cleveland

Rush University Medical Center, Chicago

Baylor College of Medicine, Houston

Oregon Health and Science University, Portland

University of California, San Francisco, San Francisco